NCT03223077 Mucosal and Microbiota Changes During Acute Campylobacteriosis
| NCT ID | NCT03223077 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Irritable Bowel Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2014-10-31 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2014-10-31 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals with Campylobacter infection are also known to develop chronic bowel problems such as Irritable Bowel Syndrome (IBS). The researchers are doing this study to understand if changes in gut bacteria and gut mucosal lining during an acute infection can help identify individuals who might be at risk for developing problems in the future.
Eligibility Criteria
Inclusion Criteria: * No abdominal surgery (except appendectomy and cholecystectomy) * Stool culture or Polymerase chain reaction (PCR) positive enteritis with Campylobacter Exclusion Criteria: * History of IBS, Irritable Bowel Disease (IBD) (Crohn's disease or ulcerative colitis), microscopic colitis or celiac disease. * History of gastroenteritis in six months prior to Campylobacter enteritis * Pregnancy
Contact & Investigator
Madhusudan Grover, MBBS
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT03223077 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Irritable Bowel Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03223077 currently recruiting?
Yes, NCT03223077 is actively recruiting participants. Contact the research team at Breen-Lyles.Margaret@mayo.edu for enrollment information.
Where is the NCT03223077 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT03223077 clinical trial?
NCT03223077 is sponsored by Mayo Clinic. The principal investigator is Madhusudan Grover, MBBS at Mayo Clinic. The trial plans to enroll 150 participants.